R1 Therapeutics

R1 Therapeutics is developing innovative, first-in-class therapies for patients with kidney disease, starting with AP306, a leading drug for treating hyperphosphatemia in chronic kidney disease patients. We are creating breakthrough treatments for millions of chronic kidney disease patients worldwide. Our team combines deep expertise in nephrology, drug development, and commercialization. The company name "R1" reflects our commitment to being at the forefront of renal care—pioneering truly innovative solutions for patients with kidney disease. Our core project, AP306, fully embodies this mission: discovering novel mechanisms of action that deliver significant clinical benefits to patients while overcoming the limitations of existing therapies.